Report cover image

Atopic Dermatitis Market Report and Forecast 2025-2034

Publisher Expert Market Research
Published Jul 28, 2025
Length 350 Pages
SKU # EMAR20319840

Description

The atopic dermatitis market attained a value of USD 9.33 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 15.10%, to reach USD 38.07 Billion by 2034.

Atopic Dermatitis Market Overview

Atopic dermatitis (AD) is a skin disease characterized by itchy, dry, and inflamed skin. It is the most common type of skin disease. The condition affects approximately 204.05 million people globally, with a prevalence rate of 2.6%. Females are more likely to suffer from AD than males, with a prevalence rate of 2.8% compared to males (2.4%). The rising prevalence of the disease is expected to augment the market size in the forecast period.

The atopic dermatitis market growth is also driven by the surge in approvals from health regulatory agencies. In December 2023 , the United States Food and Drugs Administration (FDA) approved a human monoclonal antibody known as tralokinumab-ldrm (Adbry) for children (aged 12 to 17 years old) affected from atopic dermatitis. The medication, developed by a multinational Danish pharmaceutical company LEO Pharma A/S, is the first FDA-approved interleukin (IL)-13 inhibitor that targets the main source of the skin disease’s symptoms. Such advancements in the treatment landscape of atopic dermatitis are likely to fuel the market growth.

The atopic dermatitis market demand is also pushed by the development of novel medications and effective treatment solutions. The rising awareness among patients and increasing healthcare expenditure will further aid the market growth in the coming years.

Atopic Dermatitis Market Segmentation

Atopic Dermatitis Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class
  • PDE4 Inhibitors
  • Biologics
  • Others
The market is segmented by drug class into PDE4 inhibitors, biologics, and others. PDE4 inhibitors target inflammation and reduce symptoms like itching and redness. On the other hand, biologics (used in severe cases), modulate the immune system response by blocking specific proteins.

Market Breakup by Route of Administration
  • Oral
  • Topical
  • Injectables
The atopic dermatitis market share is segmented by route of administration into oral, topical, and injectables. This segmentation reflects the different methods of medication administration available for treating atopic dermatitis.

Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom 
  
  • Germany

    •   
  • France

    •   
  • Italy

    •   
  • Spain

    •   
  • United Kingdom
    • Japan
    • China
    The market report covers 8 major markets poised to witness significant growth in the forecast period. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, along with China. North America is leading the market, owing to heightened awareness among patients regarding treatment options. The presence of an robust healthcare system, and the increased prevalence of atopic dermatitis in the region.

    Atopic Dermatitis Market: Competitor Landscape

    The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • Bristol Myers Squibb Inc.
    • Eli Lilly and Company Inc.
    • Galderma Inc.
    • Pfizer Inc.
    • Novartis AG
    • Viatris Inc.
    • Sanofi SA
    • Regeneron Pharmaceuticals, Inc.
    • Leo Pharma, Inc.
    • Incyte Corporation, Inc.
    • Arcutis Biotherapeutics, Inc.
    • Asana Biosciences, Inc.
    Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

    Key Queries Solved in the Atopic Dermatitis Market Report
    • How will the market landscape evolve in the coming years?
    • What are the major market trends influencing the market?
    • What are the major drivers, opportunities, and restraints in the market?
    • What will be the effect of each driver, challenge, and opportunity on the market?
    • Which country is poised to lead the market share in the forecast period?
    • Which country is expected to experience expedited growth during the forecast period?
    • What is the prevalence of atopic dermatitis? How is it distributed across different demographics?
    • How do factors such as the rising prevalence of atopic dermatitis impact market growth?
    • What are the different types of atopic dermatitis treatments available in the market?
    • What are the latest advancements in atopic dermatitis drug research and development?
    • Which drugs currently under clinical trials are poised to elevate the atopic dermatitis market size in forecast period?
    • What are the major drug approvals to manage atopic dermatitis during the historical period?
    • Which segment has the major impact on the market size?
    • What investments and funding are driving research and development in the market?
    • Which companies are involved in developing most advanced treatment options for patients?
    • What are the key strategies adopted by leading pharmaceutical companies to gain market share?
    • How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?
    *Please Note:* The report will take 5 business days to complete, after order confirmation.

    Table of Contents

    350 Pages
    1 Preface
    1.1 Objectives of the Study
    1.2 Key Assumptions
    1.3 Report Coverage – Key Segmentation and Scope
    1.4 Research Methodology
    2 Executive Summary
    3 Atopic Dermatitis Overview
    3.1 Guidelines and Stages
    3.2 Pathophysiology
    3.3 Screening and Diagnosis
    3.4 Treatment Pathway
    4 Patient Profile
    4.1 Patient Profile Overview
    4.2 Patient Psychology and Emotional Impact Factors
    4.3 Risk Assessment and Treatment Success Rate
    5 Atopic Dermatitis Epidemiology Analysis – 8MM
    5.1 8MM Epidemiology Scenario Overview (2018-2034)
    5.2 United States Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.3 EU-4 and United Kingdom Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.3.1 Germany Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.3.2 France Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.3.3 Italy Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.3.4 Spain Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.3.5 United Kingdom Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.4 Japan Atopic Dermatitis Epidemiology Forecast (2018-2034)
    5.5 China Atopic Dermatitis Epidemiology Forecast (2018-2034)
    6 Atopic Dermatitis Market Overview – 8MM
    6.1 Atopic Dermatitis Market Historical Value (2018-2024)
    6.2 Atopic Dermatitis Market Forecast Value (2025-2034)
    7 Atopic Dermatitis Market Landscape – 8MM
    7.1 Atopic Dermatitis: Developers Landscape
    7.1.1 Analysis by Year of Establishment
    7.1.2 Analysis by Company Size
    7.1.3 Analysis by Region
    7.2 Atopic Dermatitis Product Landscape
    7.2.1 Analysis by Drug Class
    7.2.2 Analysis by Route of Administration
    8 Atopic Dermatitis Challenges and Unmet Needs
    8.1 Treatment Pathway Challenges
    8.2 Compliance and Drop-Out Analysis
    8.3 Awareness and Prevention Gaps
    9 Cost of Treatment
    10 Atopic Dermatitis Market Dynamics
    10.1 Market Drivers and Constraints
    10.2 SWOT Analysis
    10.3 Porter’s Five Forces Model
    10.4 Key Demand Indicators
    10.5 Key Price Indicators
    10.6 Industry Events, Initiatives, and Trends
    10.7 Value Chain Analysis
    11 Atopic Dermatitis Market Segmentation – 8MM
    11.1 Atopic Dermatitis Market by Drug Class
    11.1.1 Market Overview
    11.1.2 PDE4 Inhibitors
    11.1.3 Biologics
    11.1.4 Others
    11.2 Atopic Dermatitis Market by Route of Administration
    11.2.1 Market Overview
    11.2.2 Oral
    11.2.3 Topical
    11.2.4 Injectables
    11.3 Atopic Dermatitis Market by Region
    11.3.1 Market Overview
    11.3.2 United States
    11.3.3 EU-4 and the United Kingdom
    11.3.3.1 Germany
    11.3.3.2 France
    11.3.3.3 Italy
    11.3.3.4 Spain
    11.3.3.5 United Kingdom
    11.3.4 Japan
    11.3.5 China
    12 United States Atopic Dermatitis Market
    12.1 Atopic Dermatitis Market Historical Value (2018-2024)
    12.2 Atopic Dermatitis Market Forecast Value (2025-2034)
    12.3 Atopic Dermatitis Market by Drug Class
    12.4 Atopic Dermatitis Market by Route of Administration
    13 EU-4 and United Kingdom Atopic Dermatitis Market
    13.1 Atopic Dermatitis Market Historical Value (2018-2024)
    13.2 Atopic Dermatitis Market Forecast Value (2025-2034)
    13.3 Germany Atopic Dermatitis Market Overview
    13.3.1 Atopic Dermatitis Market by Drug Class
    13.3.2 Atopic Dermatitis Market by Route of Administration
    13.4 France Atopic Dermatitis Market Overview
    13.4.1 Atopic Dermatitis Market by Drug Class
    13.4.2 Atopic Dermatitis Market by Route of Administration
    13.5 Italy Atopic Dermatitis Market Overview
    13.5.1 Atopic Dermatitis Market by Drug Class
    13.5.2 Atopic Dermatitis Market by Route of Administration
    13.6 Spain Atopic Dermatitis Market Overview
    13.6.1 Atopic Dermatitis Market by Drug Class
    13.6.2 Atopic Dermatitis Market by Route of Administration
    13.7 United Kingdom Atopic Dermatitis Market Overview
    13.7.1 Atopic Dermatitis Market by Drug Class
    13.7.2 Atopic Dermatitis Market by Route of Administration
    14 Japan Atopic Dermatitis Market
    14.1 Atopic Dermatitis Market Historical Value (2018-2024)
    14.2 Atopic Dermatitis Market Forecast Value (2025-2034)
    14.3 Atopic Dermatitis Market by Drug Class
    14.4 Atopic Dermatitis Market by Route of Administration
    15 China Atopic Dermatitis Market
    15.1 Atopic Dermatitis Market Historical Value (2018-2024)
    15.2 Atopic Dermatitis Market Forecast Value (2025-2034)
    15.3 Atopic Dermatitis Market by Drug Class
    15.4 Atopic Dermatitis Market by Route of Administration
    16 Regulatory Framework
    16.1 Regulatory Overview
    16.1.1 US FDA
    16.1.2 EU EMA
    16.1.3 JAPAN PMDA
    16.1.4 China NMPA
    17 Patent Analysis
    17.1 Analysis by Type of Patent
    17.2 Analysis by Publication year
    17.3 Analysis by Issuing Authority
    17.4 Analysis by Patent Age
    17.5 Analysis by CPC Analysis
    17.6 Analysis by Patent Valuation
    17.7 Analysis by Key Players
    18 Grants Analysis
    18.1 Analysis by year
    18.2 Analysis by Amount Awarded
    18.3 Analysis by Issuing Authority
    18.4 Analysis by Grant Application
    18.5 Analysis by Funding Institute
    18.6 Analysis by NIH Departments
    18.7 Analysis by Recipient Organization
    19 Clinical Trials Analysis
    19.1 Analysis by Trial Registration Year
    19.2 Analysis by Trial Status
    19.3 Analysis by Trial Phase
    19.4 Analysis by Therapeutic Area
    19.5 Analysis by Geography
    20 Funding and Investment Analysis
    20.1 Analysis by Funding Instances
    20.2 Analysis by Type of Funding
    20.3 Analysis by Funding Amount
    20.4 Analysis by Leading Players
    20.5 Analysis by Leading Investors
    20.6 Analysis by Geography
    21 Partnerships and Collaborations Analysis
    21.1 Analysis by Partnership Instances
    21.2 Analysis by Type of Partnership
    21.3 Analysis by Leading Players
    21.4 Analysis by Geography
    22 Supplier Landscape
    22.1 AbbVie Inc.
    22.1.1 Financial Analysis
    22.1.2 Product Portfolio
    22.1.3 Demographic Reach and Achievements
    22.1.4 Mergers and Acquisitions
    22.1.5 Certifications
    22.2 Astellas Pharma Inc.
    22.2.1 Financial Analysis
    22.2.2 Product Portfolio
    22.2.3 Demographic Reach and Achievements
    22.2.4 Mergers and Acquisitions
    22.2.5 Certifications
    22.3 Bayer AG
    22.3.1 Financial Analysis
    22.3.2 Product Portfolio
    22.3.3 Demographic Reach and Achievements
    22.3.4 Mergers and Acquisitions
    22.3.5 Certifications
    22.4 Bristol Myers Squibb Inc.
    22.4.1 Financial Analysis
    22.4.2 Product Portfolio
    22.4.3 Demographic Reach and Achievements
    22.4.4 Mergers and Acquisitions
    22.4.5 Certifications
    22.5 Eli Lilly and Company Inc.
    22.5.1 Financial Analysis
    22.5.2 Product Portfolio
    22.5.3 Demographic Reach and Achievements
    22.5.4 Mergers and Acquisitions
    22.5.5 Certifications
    22.6 Galderma Inc.
    22.6.1 Financial Analysis
    22.6.2 Product Portfolio
    22.6.3 Demographic Reach and Achievements
    22.6.4 Mergers and Acquisitions
    22.6.5 Certifications
    22.7 Pfizer Inc.
    22.7.1 Financial Analysis
    22.7.2 Product Portfolio
    22.7.3 Demographic Reach and Achievements
    22.7.4 Mergers and Acquisitions
    22.7.5 Certifications
    22.8 Novartis AG
    22.8.1 Financial Analysis
    22.8.2 Product Portfolio
    22.8.3 Demographic Reach and Achievements
    22.8.4 Mergers and Acquisitions
    22.8.5 Certifications
    22.9 Viatris Inc.
    22.9.1 Financial Analysis
    22.9.2 Product Portfolio
    22.9.3 Demographic Reach and Achievements
    22.9.4 Mergers and Acquisitions
    22.9.5 Certifications
    22.10 Sanofi SA
    22.10.1 Financial Analysis
    22.10.2 Product Portfolio
    22.10.3 Demographic Reach and Achievements
    22.10.4 Mergers and Acquisitions
    22.10.5 Certifications
    22.11 Regeneron Pharmaceuticals, Inc.
    22.11.1 Financial Analysis
    22.11.2 Product Portfolio
    22.11.3 Demographic Reach and Achievements
    22.11.4 Mergers and Acquisitions
    22.11.5 Certifications
    22.12 Leo Pharma, Inc.
    22.12.1 Financial Analysis
    22.12.2 Product Portfolio
    22.12.3 Demographic Reach and Achievements
    22.12.4 Mergers and Acquisitions
    22.12.5 Certifications
    22.13 Incyte Corporation, Inc.
    22.13.1 Financial Analysis
    22.13.2 Product Portfolio
    22.13.3 Demographic Reach and Achievements
    22.13.4 Mergers and Acquisitions
    22.13.5 Certifictions
    22.14 Arcutis Biotherapeutics, Inc.
    22.14.1 Financial Analysis
    22.14.2 Product Portfolio
    22.14.3 Demographic Reach and Achievements
    22.14.4 Mergers and Acquisitions
    22.14.5 Certifications
    22.15 Asana Biosciences, Inc.
    22.15.1 Financial Analysis
    22.15.2 Product Portfolio
    22.15.3 Demographic Reach and Achievements
    22.15.4 Mergers and Acquisitions
    22.15.5 Certifications
    23 Atopic Dermatitis Market- Distribution Model (Additional Insight)
    23.1 Overview
    23.2 Potential Distributors
    23.3 Key Parameters for Distribution Partner Assessment
    24 Key Opinion Leaders (KOL) Insights (Additional Insight)
    25 Company Competitiveness Analysis (Additional Insight)
    25.1 Very Small Companies
    25.2 Small Companies
    25.3 Mid-Sized Companies
    25.4 Large Companies
    25.5 Very Large Companies
    26 Payment Methods (Additional Insight)
    26.1 Government Funded
    26.2 Private Insurance
    26.3 Out-of-Pocket

    Pricing

    Currency Rates
    How Do Licenses Work?

    How Do Licenses Work?

    The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

    • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

    • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

    • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

    • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

    • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

    License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
    Chat Now
    Contact Us